EUVIMEDEUVIMED entdecken
Crossref

Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure

Eshat F Haque, Ryosuke Tanino, Tamio Okimoto, Takamasa Hotta, Takae Okuno, Kento Kono, Yukari Tsubata, Takeshi Isobe

Anticancer Research · 2026

DOI: 10.21873/anticanres.18032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Eshat F Haque und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan. Hauptthemen laut MEDLINE: Pemetrexed, Mutation, Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Resistance to targeted therapy limits its efficacy in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although concurrent administration of pemetrexed (PEM) and EGFR-tyrosine kinase inhibitors (TKIs) has yielded clinical benefits, it remains unclear whether concurrent PEM influences de novo mutations in the EGFR-TKI therapy. To address this gap, we aimed to compare the time to acquired resistance and accumulation of de novo tumor mutational burden (TMB) during in vitro exposure to osimertinib (OSI) and gefitinib (GEF), as well as their respective combinations with PEM. MATERIALS AND METHODS: EGFR-mutated PC-9 cells were continuously exposed to EGFR-TKIs, alone or in combination with PEM, at equimolar concentrations. The drug concentration gradually increased to 1 and 3 μM for OSI and GEF, respectively. Whole-exome sequencing and quantitative PCR were performed to measure TMB and gene expression, respectively. RESULTS: Concurrent PEM with either OSI or GEF extended the treatment duration compared to single EGFR-TKIs, decreased the de novo accumulated TMB per treatment time, and increased the expression of POLE2, POLQ, MLH1, BRCA1, BRCA2, RAD51, and FEN1 compared to that of single EGFR-TKIs. CONCLUSION: Concurrent PEM with EGFR-TKI treatment slowed TMB accumulation rate and resistance acquisition in EGFR-mutated NSCLC compared to single EGFR-TKIs in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemetrexedMutationProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansErbB ReceptorsAniline CompoundsCell Line, TumorGefitinibDrug Resistance, NeoplasmPyrimidinesIndolesAcrylamides

Stichwörter der Autor:innen

Concurrent therapyEGFR-TKIpemetrexedtumor mutational burden

Substanzen

PemetrexedErbB ReceptorsProtein Kinase InhibitorsAniline CompoundsEGFR protein, humanGefitinibPyrimidinesosimertinibIndolesAcrylamides

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
  • Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan okimoto@med.shimane-u.ac.jp.

Zitieren

APA

Haque, E. F., Tanino, R., Okimoto, T., Hotta, T., Okuno, T., Kono, K., Tsubata, Y., & Isobe, T. (2026). Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure. Anticancer Research. https://doi.org/10.21873/anticanres.18032

Vancouver

Haque EF, Tanino R, Okimoto T, Hotta T, Okuno T, Kono K, et al. Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure. Anticancer Research. 2026. doi:10.21873/anticanres.18032

BibTeX
@article{Haque2026,
  author = {Haque, Eshat F and Tanino, Ryosuke and Okimoto, Tamio and Hotta, Takamasa and Okuno, Takae and Kono, Kento and Tsubata, Yukari and Isobe, Takeshi},
  title = {Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18032}
}
Kostenlos starten →